We are pleased to announce that we have recently signed a USD 250 million contract with Artemis DNA. Artemis DNA is a leading US-based diagnostic laboratory company providing proprietary next generation sequencing (NGS) gene tests and diagnostic laboratory services for a variety of medical specialities, including cardiology, oncology, immunology, neurology, reproductive medicine and pharmacogenomics. Under the five-year exclusive agreement, Artemis DNA will distribute Trucheck™ Pragma and Cancertrack in the US and Vietnam.
Trucheck™ Pragma is a minimally invasive, blood-based screening test for lung, gastric, colorectal, pancreatic, prostate, breast and ovarian cancer. Cancertrack is a monitoring test designed to detect recurrences or progression of cancer at the earliest possible stage, thus enabling therapy to be adapted. The two analyses are currently offered as “Laboratory Developed Tests” (LDTs) in the USA.
Find the detailed article here: : https://www.pressebox.de/pressemitteilung/datar-cancer-genetics-europe-gmbh/datar-cancer-genetics-expandiert-in-die-usa/boxid/1112243